Stelara market seen growing to $15.57 million by 2030

The Business Research Company says the Stelara (ustekinumab) market will rise from $11.85 million in 2025 to $15.57 million by 2030, driven by autoimmune disease growth, broader biologic use and longer-lasting treatment demand. North America led in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Stelara’s market growth tracks rising demand for biologic therapies used to treat chronic autoimmune diseases. - The forecast points to continued commercial opportunity in psoriasis and inflammatory bowel disease as patient counts and diagnosis rates increase. - Competition from biosimilars and better delivery systems could reshape pricing, access and adoption over the next several years.

What happened: - The Business Research Company released a 2026 market report on Stelara (ustekinumab) on Nov. 12, 2026. - The report projects the market will grow from $11.85 million in 2025 to $12.54 million in 2026. - The report forecasts the market will reach $15.57 million by 2030. - The report places North America as the largest regional market in 2025. - The report identifies Asia-Pacific as the fastest-growing region during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company offers a free sample report and a full market report.

The details: - Stelara is a monoclonal antibody that targets interleukin-12 and interleukin-23. - The drug is used for moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. - The report ties earlier market growth to limitations of traditional immunosuppressants, higher autoimmune disease prevalence, strong clinical efficacy data, hospital-based biologic administration and demand for durable remission. - The report links future growth to rising inflammatory bowel disease cases, broader reimbursement for biologic therapies, preference for less frequent dosing, biosimilar competition and biologic delivery advances. - Psoriasis remains a major demand driver because Stelara reduces inflammation and plaque buildup, improving skin clearance and long-term symptom control. - The National Psoriasis Foundation said in August 2024 that roughly 3% of U.S. adults age 20 and older, or more than 7 million people, have psoriasis. - The National Psoriasis Foundation also estimated that about 600,000 U.S. adults may have psoriasis without a diagnosis. - The report says improved diagnostics, environmental factors, genetic predisposition and an aging population are contributing to psoriasis growth. - The 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The report frames Stelara’s growth as a mix of clinical need and market structure, not just prescription volume. - Biosimilar competition appears to be both a threat and a signal that the category is maturing. - The emphasis on reimbursement and dosing convenience suggests access and adherence will be as important as efficacy in the next phase of the market.

What's next: - The market is expected to keep expanding through 2030, though at a slower growth rate than the initial rebound from 2025 to 2026. - Regional growth outside North America may become more important as healthcare access expands in Asia-Pacific. - More competition from biosimilars could pressure the market while also broadening treatment access.

The bottom line: - Stelara remains a meaningful autoimmune drug market, but its next growth phase will depend on reimbursement, access, dosing convenience and competition as much as on disease prevalence.